Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» US FDA accepts Abbott's six-month 45-mg formulation of Lupron sNDA for review
US FDA accepts Abbott's six-month 45-mg formulation of Lupron sNDA for review
US FDA accepts Abbott's six-month 45-mg formulation of Lupron sNDA for review
Submitted by
admin
on March 13, 2010 - 11:07am
Source:
Pharmabiz
News Tags:
Abbott Laboratories
Lupron
prostate cancer
Headline:
US FDA accepts Abbott's six-month 45-mg formulation of Lupron sNDA for review
Do Not Allow Advertisers to Use My Personal information
